Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A systematic cochrane review of corrector therapies (with or without potentiators) for people with cystic fibrosis with class II gene variants (most commonly F508DEL).

Paediatric respiratory reviews - 1 Jun 2021

Southern K W, Murphy J, Sinha I P, Nevitt S J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, MHC Class II

Share to Mutation

Source

Identifiers

PMID: 33875358
DOI: 10.1016/j.prrv.2021.03.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A systematic cochrane review of corrector therapies (with or without potentiators) for people with cystic fibrosis with class II gene variants (most commonly F508DEL).PMID 33875358Read ↗

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).Semantic proximity Read ↗

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).Semantic proximity Read ↗

Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.Semantic proximity Read ↗

Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.Semantic proximity Read ↗

New drugs in cystic fibrosis: what has changed in the last decade?Semantic proximity Read ↗

Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.Semantic proximity Read ↗

Corrector combination therapies for F508del-CFTR.Semantic proximity Read ↗

CFTR potentiators: not an open and shut case.Semantic proximity Read ↗

Potentiators for cystic fibrosis - targeting the underlying molecular defect.Semantic proximity Read ↗

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis.Semantic proximity Read ↗

New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.Semantic proximity Read ↗

Toward inclusive therapy with CFTR modulators: Progress and challengesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.